Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Celator Claims Phase III Vyxeos Victory In AML

This article was originally published in Scrip

Executive Summary

Celator Pharmaceuticals Inc. more than quadrupled in after-hours trading on March 14 after the company reported Phase III overall survival (OS) data for Vyxeos (CPX-351) that could support US and EU approvals for the first new acute myeloid leukemia (AML) therapy in almost 40 years.


Related Content

Celator Shines At ASCO, Highlights Upside For Jazz
Ten Programs To Watch Out For At ASCO





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst